Mineralys Therapeutics, Inc.
MLYS
$39.20
$0.050.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 14.32% | 28.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.01% | 5.17% | |||
| Operating Income | 12.01% | -5.17% | |||
| Income Before Tax | 14.66% | -2.52% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 14.66% | -2.52% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 14.66% | -2.52% | |||
| EBIT | 12.01% | -5.17% | |||
| EBITDA | 12.01% | -5.17% | |||
| EPS Basic | 20.87% | 16.73% | |||
| Normalized Basic EPS | 20.86% | 16.73% | |||
| EPS Diluted | 20.87% | 16.73% | |||
| Normalized Diluted EPS | 20.86% | 16.73% | |||
| Average Basic Shares Outstanding | 7.86% | 23.11% | |||
| Average Diluted Shares Outstanding | 7.86% | 23.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||